FIGURE

Fig. 4

ID

ZDB-FIG-250327-4

Publication

Hua et al., 2025 - Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

The inhibitory effect of anlotinib combined with osimertinib on NSCLC cell proliferation was investigated in vivo in zebrafish xenograft models. (A) Representative images and quantitative analysis of cell proliferation in the H1975 and PC9 zebrafish xenograft models (scale bar, 500 µm). (B) Representative images and quantitative analysis of cell proliferation in the H1975-OR and PC9-OR zebrafish xenograft models (scale bar, 500 µm). The number of xenografts analyzed is indicated in the corresponding images. P values were calculated by unpaired Student’s t-tests; *, P<0.05; **, P<0.01; ***, P<0.001; NS, not significant. Each data point represents an independent biological replicate. NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib; NSCLC, non-small cell lung cancer.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Transl Lung Cancer Res